LGVN
Longeveron Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.81
+3.50%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$21.71M
MomentumView details →
1D Return
+3.50%
YTD Return
+1237.35%
RSI (14)
89.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$21.71M
RSI (14)
89.4
MomentumView details →
1D Return
+3.50%
YTD Return
+1237.35%
SummaryUpdated Jun 1, 2026
Longeveron Inc. (NASDAQ:LGVN) is a clinical-stage biotechnology company founded in 2014 and based in Miami, Florida. The company went public in February 2021 and focuses on developing cellular therapies for aging-related and life-threatening conditions. Longeveron's primary focus is advancing its lead investigational product, LOMECEL-B, a cell-based therapy derived from bone marrow of young healthy adult donors, through various clinical trials targeting rare diseases and age-related conditions.
Similar companies
Latest newsMore news →
Longeveron Inc. announced a 1-for-10 reverse split of its Class A and Class B common stock, previously approved by stockholders on July 1, 2026 and by the board on July 31, 2026.11d agoLongeveron Inc. appointed Nirav S. Jhaveri as Chief Financial Officer, principal financial officer and principal accounting officer, effective August 17, 2026.17d ago